Waystar vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Waystar is a healthcare payments and revenue cycle technology platform processing over $5 trillion in claims annually for hospitals, health systems, and physician groups.
About
Waystar is a healthcare technology company formed through the 2019 merger of ZirMed and Navicure that provides cloud-based revenue cycle management technology to healthcare providers. The platform automates the complex workflows involved in healthcare payments including eligibility verification, claims submission, denial management, payment posting, and patient payment collection. Waystar processes over $5 trillion in annual claims for a network of over 1,000 health plan and payer connections, making it one of the largest healthcare clearinghouse and RCM technology providers in the United States. The company serves hospitals, health systems, physician practices, and ancillary care providers of all sizes through a SaaS platform that integrates with major EHR systems. Waystar went public on Nasdaq in 2024 following years of private equity ownership under EQT Partners. The company uses AI to improve claim accuracy before submission, prioritize denial appeals, and automate patient payment workflows. Waystar's scale and network of payer connections make it a critical piece of healthcare financial infrastructure for providers seeking to improve cash flow and reduce administrative costs.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.